Volume 5.41 | Oct 31

Prostate Cell News 5.41 October 31, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Elevated LIM Kinase 1 in Non-Metastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation
A LIMK selective small molecule inhibitor (LIMKi) was used to determine whether targeted LIMK inhibition was a potential prostate cancer (PC) therapy. LIMKi reduced PC cell motility, as well as inhibiting proliferation and increasing apoptosis in androgen-dependent PC cells more effectively than in androgen-independent PC cells. [Mol Cancer Ther] Abstract | Full Article
[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.
PUBLICATIONS (Ranked by impact factor of the journal)

Nuclear iASPP May Facilitate Prostate Cancer Progression
Researchers identified inhibitor of apoptosis-stimulating protein of p53 (iASPP), a common cellular regulator of p53 and p63, as an important player of prostate cancer progression. [Cell Death Dis] Full Article

ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer
Genomic analysis of ERG siRNA-treated prostate cells harboring the endogenous TMPRSS2-ERG fusion revealed an inverse relationship between ERG and Annexin A2 (ANXA2) expression at both the RNA and protein level. ERG overexpression disrupted ANXA2 mediated cell polarity and promoted epithelial mesenchymal transition by inhibiting CDC42 and RHOA, and by activating cofilin. [Mol Cancer Res] Abstract

HIF-1alpha Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
To further analyze the consequences of hypoxic upregulation on stem cell proliferation and hypoxia-inducible factor 1alpha signaling, cancer stem cells subpopulations from murine TRAMP-C1 cells as well as from a human prostate cancer cell line were isolated and characterized. [Mol Cancer Res] Abstract

N-3 Polyunsaturated Fatty Acids Inhibit IFN-γ-Induced IL-18 Binding Protein Production by Prostate Cancer Cells
Investigators demonstrate that n-3 polyunsaturated fatty acids treatment significantly reduced interferon (IFN)-γ-induced IL-18BP production by DU-145 and PC-3 prostate cancer cells by inhibiting IL-18BP mRNA expression and was associated with a reduction in IFN-γ receptor expression. [Cancer Immunol Immunother] Abstract

Epithelial-Mesenchymal Transition in Prostate Cancer Is Associated with Quantifiable Changes in Nuclear Structure
Researchers determined whether epithelial and mesenchymal prostate cancer cells have different nuclear morphology. Murine tibia injections of epithelial PC3 and mesenchymal PC3 prostate cancer cells were processed and stained with H&E. [Prostate] Abstract

Nobiletin Suppresses Cell Viability through AKT Pathways in PC-3 and DU-145 Prostate Cancer Cells
Scientists investigated the effects of nobiletin in prostate cancer cell lines PC-3 and DU-145. Data showed that nobiletin decreased cell viability in both prostate cell lines, with a greater reduction in viability in PC-3 cells. [BMC Pharmacol Toxicol] Full Article


Efficacy and Safety of Radium-223 Dichloride in Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases, with or without Previous Docetaxel Use: A Prespecified Subgroup Analysis from the Randomized, Double-Blind, Phase III ALSYMPCA Trial
Researchers analyzed a prespecified subgroup from ALSYMPCA to assess the effect of previous docetaxel use on the efficacy and safety of radium-223. [Lancet Oncol] Abstract

99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
Under an exploratory investigational new drug, using a cross-over design, the authors compared the pharmacokinetics, biodistribution, and tumor uptake of 99mTc-MIP-1404 and 99mTc-MIP-1405 in six healthy men and six men with radiographic evidence of metastatic prostate cancer. [J Nucl Med] Abstract

Learn About the CFU Assay as an In Vitro Tool for Predicting In Vivo Cytopenia Earlier in Drug Development - Free White Paper
Androgens and Androgen Receptor Signaling in Prostate Tumorigenesis
The authors summarize the current state of knowledge concerning the role of androgens and androgen receptor (AR) signaling in prostate tissue, from development to metastatic, castration-resistant prostate cancer and use that information to suggest potential roles for androgens and AR in prostate cancer initiation. [J Mol Endocrinol] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
In Year Two, MD Anderson Moon Shots Program Begins to Generate Innovations
Improved surgical outcomes for ovarian cancer, expanded potential impact for new drugs, and a novel family outreach program to head off cancers fueled by known genetic risk mutations are among the early innovations of The University of Texas MD Anderson Cancer Center’s Moon Shots Program. [The University of Texas MD Anderson Cancer Center] Press Release

TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease
TapImmune, Inc. provided an update on the status of its PolyStart™ vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. [TapImmune, Inc.] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
New Prostate Cancer Screening Guideline Recommends Not Using PSA Test
A new Canadian guideline recommends that the prostate-specific antigen (PSA) test should not be used to screen for prostate cancer based on evidence that shows an increased risk of harm and uncertain benefits. [Canadian Medical Association Journal (EurekAlert)] Editorial | Full Article

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 5th International Conference on Stem Cells and Cancer (ICSCC-2014): Proliferation, Differentiation and Apoptosis
November 8-10, 2014
New Delhi, India

NEW Tumor Immunology and Immunotherapy: A New Chapter
December 1-4, 2014
Orlando, United States

NEW Keystone Symposia – Epigenetics and Cancer
January 25-30, 2015
Keystone, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellow – Metabolomics and Prostate Cancer (University of Maryland)

Senior Research Associate – Nanomedicine (University of East Anglia)

Postdoctoral Fellow – Role of Deregulated PTEN/FOXO1 Pathway in Prostate Cancer (Mayo Clinic)

Postdoctoral Fellow – Oncology (Johnson & Johnson Pharmaceutical Research & Development)

Postdoctoral Fellow – Prognostic Biomarkers for Prostate Cancer (McGill University)

Physician Scientist – Prostate Cancer Genomics (University of Chicago)

Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Postdoctoral Position – Bioinformatics for Prostate Cancer (CRUK Manchester Institute)

Postdoctoral Fellows and Graduate Student Positions (Vancouver Prostate Centre)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us